318 related articles for article (PubMed ID: 36578492)
1. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
[TBL] [Abstract][Full Text] [Related]
3. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of inflammatory myopathies: a review.
Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
[TBL] [Abstract][Full Text] [Related]
5. The risk of ischemic stroke in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.
Zhen C; Wang Y; Wang H; Wang X
Clin Rheumatol; 2021 Oct; 40(10):4101-4108. PubMed ID: 33934269
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis.
Mandel DE; Malemud CJ; Askari AD
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524083
[TBL] [Abstract][Full Text] [Related]
7. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.
Moghadam-Kia S; Oddis CV; Aggarwal R
Clin Rev Allergy Immunol; 2017 Feb; 52(1):81-87. PubMed ID: 26767526
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
9. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
[TBL] [Abstract][Full Text] [Related]
13. From data to diagnosis: how machine learning is revolutionizing biomarker discovery in idiopathic inflammatory myopathies.
McLeish E; Slater N; Mastaglia FL; Needham M; Coudert JD
Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38243695
[TBL] [Abstract][Full Text] [Related]
14. Current diagnosis and treatment of polymyositis and dermatomyositis.
Sasaki H; Kohsaka H
Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
[TBL] [Abstract][Full Text] [Related]
18. The effects of infliximab in treating idiopathic inflammatory myopathies: A review article.
Ge Y; Li S; Chen F; He L; Li C; Lu X; Wang G
Dermatol Ther; 2021 Jul; 34(4):e14976. PubMed ID: 33991036
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Idiopathic Inflammatory Myopathies in Africa: A Contemporary Systematic Review.
Essouma M; Noubiap JJ; Singwe-Ngandeu M; Hachulla E
J Clin Rheumatol; 2022 Mar; 28(2):e552-e562. PubMed ID: 33843773
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: A meta-analysis of randomized controlled trials.
Chang D; Gong M; Liu C; Zhang Q; Hu Z; Li Z
Med Clin (Barc); 2021 Nov; 157(9):418-426. PubMed ID: 33070945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
